Scinai Immunotherapeutics Ltd.

SCNI Nasdaq CIK: 0001611747

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filer
State of Incorporation Israel
Business Address JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM, L3, 00000
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM, L3, 00000
Phone 972-8-9302529
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025 FY

$1.31M
Revenue
$13.45M
Total Assets
$9.98M
Stockholders' Equity
$4.87M
Cash & Equivalents
$0.00
EPS

Recent SEC Filings

Form Type Date Filed Document
20-F Foreign company annual report April 1, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
6-K Foreign company current report March 23, 2026 View on SEC
6-K Foreign company current report March 19, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC

Annual Reports

20-F April 1, 2026
  • Dual-engine business model combining proprietary NanoAbs drug development with CDMO service revenue.
  • Lead project SCIN-11 shows potential in treating inflammation and autoimmune conditions.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.